Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus

Nature Medicine

Volumn 11, Issue 7, 2005, Pages 740-747

  Edghill Smith, Yvette ^a   Golding, Hana ^b   Manischewitz, Jody ^b   King, Lisa R ^b   Scott, Dorothy ^b   Bray, Mike ^c   Nalca, Aysegul ^d   Hooper, Jay W ^e   Whitehouse, Chris A ^e   Schmitz, Joern E ^f   Reimann, Keith A ^f   Franchini, Genoveffa ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d SOUTHERN RESEARCH INSTITUTE   (United States)

^e UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CM T807; MONOCLONAL ANTIBODY OKT4A IMMUNOGLOBULIN G1; PALIVIZUMAB; RITUXIMAB; SMALLPOX VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE SEVERITY; HUMORAL IMMUNITY; LYMPHOCYTE DEPLETION; MACACA; MEMORY CELL; MONKEYPOX; MONKEYPOX VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; ORTHOLOGY; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RHESUS MONKEY; SMALLPOX VIRUS; T LYMPHOCYTE;

ANIMALS; ANTIBODIES; ANTIBODY FORMATION; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; IMMUNOLOGIC MEMORY; MACACA MULATTA; MONKEYPOX; MONKEYPOX VIRUS; SMALLPOX VACCINE;

ANIMALIA; MACACA; MACACA MULATTA; MONKEYPOX VIRUS; VACCINIA; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 22544457889     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1261     Document Type: Article

References (35)

1. Bray, M. & Buller, M. Looking back at smallpox. Clin. Infect. Dis. 38, 882-889 (2004).
2. Fenner, F., Henderson, D.A., Arita, I., Jezek, Z. & Ladnyi, I. Smallpox and its eradication (World Health Organization, Geneva, 1988).
3. Bray, M. & Wright, M.E. Progressive vaccinia. Clin. Infect. Dis. 36, 766-774 (2003).
4. Kemper, A.R., Davis, M.M. & Freed, G.L. Expected adverse events in a mass smallpox vaccination campaign. Eff. Clin. Pract. 5, 84-90 (2002).
5. Henderson, D.A. et al. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. J. Am. Med. Assoc. 281, 2127-2137 (1999).
6. Earl, P.L. et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428, 182-185 (2004).
7. Hooper, J.W. et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 78, 4433-4443 (2004).
8. Weltzin, R. et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat. Med. 9, 1125-1130 (2003).
9. Zaucha, G.M., Jahrling, P.B., Geisbert, T.W., Swearengen, J.R. & Hensley, L. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab. Invest. 81, 1581-1600 (2001).
10. Edghill-Smith, Y. et al. Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. J. Infect. Dis. 188, 1181-1191 (2003).
11. + lymphocytes using a mouse-human chimeric monoclonal antibody. Am. J. Pathol. 154, 1923-1932 (1999).
12. Reff, M.E. et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435-445 (1994).
13. Schmitz, J.E. et al. Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J. Virol. 77, 2165-2173 (2003).
14. Manischewitz, J. et al. Development of a novel vaccinia-neutralization assay based on reporter-gene expression. J. Infect. Dis. 188, 440-448 (2003).
15. Kulesh, D.A. et al. Smallpox and pan-orthopox virus detection by real-time 3′-minor groove binder TaqMan assays on the Roche LightCycler and the Cepheid Smart Cycler platforms. J. Clin. Microbiol. 42, 601-609 (2004).
16. Mourad, G.J. et al. Humanized IgG1 and IgG4 anti-CD4 monoclonal antibodies: effects on lymphocytes in the blood, lymph nodes, and renal allografts in cynomolgus monkeys. Transplantation 65, 632-641 (1998).
17. Mack, T.M., Noble, J., Jr & Thomas, D.B. A prospective study of serum antibody and protection against smallpox. Am. J. Trop. Med. Hyg. 21, 214-218 (1972).
18. Sarkar, J.K., Mitra, A.C. & Mukherjee, M.K. The minimum protective level of antibodies in smallpox. Bull. World Health Organ. 52, 307-311 (1975).
19. Edghill-Smith, Y. et al. Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge. J. Infect. Dis. 191, 372-381 (2005).
20. Wyatt, L.S., Earl, P.L., Eller, L.A. & Moss, B. Highly attenuated smallpox vaccine | protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc. Natl Acad. Sci. USA 101, 4590-4595 (2004).
21. Belyakov, I.M. et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl Acad. Sci. USA 100, 9458-9463 (2003).
22. Salk, J. & Salk, D. Control of influenza and poliomyelitis with killed virus vaccines. Science 195, 834-847 (1977).
23. Duncan, S.A. & Smith, G.L. Identification and characterization of an extracellular envelope glycoprotein affecting vaccinia virus egress. J. Virol. 66, 1610-1621 (1992).
24. Engelstad, M., Howard, S.T. & Smith, G.L. A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology 188, 801-810 (1992).
25. Hirt, P., Hiller, G. & Wittek, R. Localization and fine structure of a vaccinia virus gene encoding an envelope antigen. J. Virol. 58, 757-764 (1986).
26. Isaacs, S.N., Wolffe, E.J., Payne, L.G. & Moss, B. Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope. J. Virol. 66, 7217-7224 (1992).
27. Roper, R.L., Payne, L.G. & Moss, B. Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene. J. Virol. 70, 3753-3762 (1996).
28. Centers for Disease Control and Prevention. Multistate outbreak of monkeypox-Illinois, Indiana, and Wisconsin, 2003. Morb. Mortal. Wkly. Rep. 52, 537-540 (2003).
29. Centers for Disease Control and Prevention. Update: multistate outbreak of monkeypox-Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. Morb. Mortal. Wkly. Rep. 52, 642-646 (2003).
30. Ladnyi, I.D., Ziegler, P. & Kima, E. A human infection caused by monkey pox virus in Basankusu Territory, Democratic Republic of the Congo. Bull. World Health Organ. 55, 613-623 (1972).
31. Marennikova, S.S. et al. Monkey pox in humans: current results. Acta Virol. 33, 246-253 (1989).
32. Tartaglia, J. et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188, 217-232 (1992).
33. Moss, B. et al. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv. Exp. Med. Biol. 397, 7-13 (1996).
34. Hooper, J.W., Custer, D.M. & Thompson, E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306, 181-195 (2003).
35. Chakrabarti, S., Sisler, J.R. & Moss, B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23, 1094-1097 (1997).